Sara Moghadam Farid, Aida Iraji, Somayeh Mojtabavi, Mehrnaz Ghasemi, Mohammad Ali Faramarzi, Mohammad Mahdavi, Maliheh Barazandeh Tehrani, Tahmineh Akbarzadeh and Mina Saeedi
{"title":"喹唑啉酮-1,2,3-三唑-乙酰胺偶联物作为有效的α-葡萄糖苷酶抑制剂:合成、酶抑制、动力学分析和分子对接研究†‡","authors":"Sara Moghadam Farid, Aida Iraji, Somayeh Mojtabavi, Mehrnaz Ghasemi, Mohammad Ali Faramarzi, Mohammad Mahdavi, Maliheh Barazandeh Tehrani, Tahmineh Akbarzadeh and Mina Saeedi","doi":"10.1039/D2MD00297C","DOIUrl":null,"url":null,"abstract":"<p >In this study, new hybrids of quinazolinone-1,2,3-triazole-acetamide were designed, synthesized, and screened for their α-glucosidase inhibitory activity. The results obtained from the <em>in vitro</em> screening indicated that all analogs exhibited significant inhibitory activity against α-glucosidase (IC<small><sub>50</sub></small> values ranging from 4.8–140.2 μM) in comparison to acarbose (IC<small><sub>50</sub></small> = 750.0 μM). The limited structure–activity relationships suggested the variation in the inhibitory activities of the compounds affected by different substitutions on the aryl moiety. The enzyme kinetic studies of the most potent compound <strong>9c</strong>, revealed that it inhibited α-glucosidase in a competitive mode with a <em>K</em><small><sub>i</sub></small> value of 4.8 μM. In addition, molecular docking studies investigated the structural perturbation and behavior of all derivatives inside the α-glucosidase active site. Next, molecular dynamic simulations of the most potent compound <strong>9c</strong>, were performed to study the behavior of the <strong>9c</strong>-complex during the time. The results showed that these compounds can be considered as potential antidiabetic agents.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 3","pages":" 520-533"},"PeriodicalIF":3.5970,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2023/md/d2md00297c?page=search","citationCount":"1","resultStr":"{\"title\":\"Quinazolinone-1,2,3-triazole-acetamide conjugates as potent α-glucosidase inhibitors: synthesis, enzyme inhibition, kinetic analysis, and molecular docking study†‡\",\"authors\":\"Sara Moghadam Farid, Aida Iraji, Somayeh Mojtabavi, Mehrnaz Ghasemi, Mohammad Ali Faramarzi, Mohammad Mahdavi, Maliheh Barazandeh Tehrani, Tahmineh Akbarzadeh and Mina Saeedi\",\"doi\":\"10.1039/D2MD00297C\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >In this study, new hybrids of quinazolinone-1,2,3-triazole-acetamide were designed, synthesized, and screened for their α-glucosidase inhibitory activity. The results obtained from the <em>in vitro</em> screening indicated that all analogs exhibited significant inhibitory activity against α-glucosidase (IC<small><sub>50</sub></small> values ranging from 4.8–140.2 μM) in comparison to acarbose (IC<small><sub>50</sub></small> = 750.0 μM). The limited structure–activity relationships suggested the variation in the inhibitory activities of the compounds affected by different substitutions on the aryl moiety. The enzyme kinetic studies of the most potent compound <strong>9c</strong>, revealed that it inhibited α-glucosidase in a competitive mode with a <em>K</em><small><sub>i</sub></small> value of 4.8 μM. In addition, molecular docking studies investigated the structural perturbation and behavior of all derivatives inside the α-glucosidase active site. Next, molecular dynamic simulations of the most potent compound <strong>9c</strong>, were performed to study the behavior of the <strong>9c</strong>-complex during the time. The results showed that these compounds can be considered as potential antidiabetic agents.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 3\",\"pages\":\" 520-533\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2023-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.rsc.org/en/content/articlepdf/2023/md/d2md00297c?page=search\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2023/md/d2md00297c\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"3","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2023/md/d2md00297c","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Quinazolinone-1,2,3-triazole-acetamide conjugates as potent α-glucosidase inhibitors: synthesis, enzyme inhibition, kinetic analysis, and molecular docking study†‡
In this study, new hybrids of quinazolinone-1,2,3-triazole-acetamide were designed, synthesized, and screened for their α-glucosidase inhibitory activity. The results obtained from the in vitro screening indicated that all analogs exhibited significant inhibitory activity against α-glucosidase (IC50 values ranging from 4.8–140.2 μM) in comparison to acarbose (IC50 = 750.0 μM). The limited structure–activity relationships suggested the variation in the inhibitory activities of the compounds affected by different substitutions on the aryl moiety. The enzyme kinetic studies of the most potent compound 9c, revealed that it inhibited α-glucosidase in a competitive mode with a Ki value of 4.8 μM. In addition, molecular docking studies investigated the structural perturbation and behavior of all derivatives inside the α-glucosidase active site. Next, molecular dynamic simulations of the most potent compound 9c, were performed to study the behavior of the 9c-complex during the time. The results showed that these compounds can be considered as potential antidiabetic agents.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.